Sangamo Therapeutics Inc [NASDAQ: SGMO] plunged by -$0.03 during the normal trading session on Wednesday and reaching a high of $0.4349 during the day while it closed the day at $0.39.
Sangamo Therapeutics Inc stock has also loss -16.57% of its value over the past 7 days. However, SGMO stock has declined by -31.59% in the 3 months of the year. Over the past six months meanwhile, it has lost -21.58% and lost -80.87% year-on date.
The market cap for SGMO stock reached $131.94 million, with 336.49 million shares outstanding and 328.57 million shares in the current float. Compared to the average trading volume of 4.88M shares, SGMO reached a trading volume of 6313429 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sangamo Therapeutics Inc [SGMO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SGMO shares is $3.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SGMO stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Sangamo Therapeutics Inc shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on November 07, 2025. The new note on the price target was released on December 13, 2024, representing the official price target for Sangamo Therapeutics Inc stock. Previously, the target price had yet another raise to $10, while H.C. Wainwright analysts kept a Buy rating on SGMO stock. On November 03, 2023, analysts decreased their price target for SGMO shares from 6 to 2.
The Price to Book ratio for the last quarter was 20.22, with the Price to Cash per share for the same quarter was set at 0.09.
SGMO stock trade performance evaluation
Sangamo Therapeutics Inc [SGMO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.57. With this latest performance, SGMO shares dropped by -39.16% in over the last four-week period, additionally sinking by -21.58% over the last 6 months – not to mention a drop of -61.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SGMO stock in for the last two-week period is set at 27.41, with the RSI for the last a single of trading hit 0.0447, and the three-weeks RSI is set at 0.0477 for Sangamo Therapeutics Inc [SGMO]. The present Moving Average for the last 50 days of trading for this stock 0.5867, while it was recorded at 0.4237 for the last single week of trading, and 0.6518 for the last 200 days.
Sangamo Therapeutics Inc [SGMO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sangamo Therapeutics Inc [SGMO] shares currently have an operating margin of -335.55% and a Gross Margin at 76.11%. Sangamo Therapeutics Inc’s Net Margin is presently recorded at -331.28%.
Sangamo Therapeutics Inc (SGMO) Capital Structure & Debt Analysis
According to recent financial data for Sangamo Therapeutics Inc. ( SGMO), the Return on Equity (ROE) stands at -480.02%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -108.96%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Sangamo Therapeutics Inc’s Return on Invested Capital (ROIC) is -343.92%, showcasing its effectiveness in deploying capital for earnings.
Sangamo Therapeutics Inc (SGMO) Efficiency & Liquidity Metrics
Based on Sangamo Therapeutics Inc’s (SGMO) latest financial statements, the Debt-to-Equity Ratio is 4.07%, indicating its reliance on debt financing relative to shareholder equity.
Sangamo Therapeutics Inc (SGMO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Sangamo Therapeutics Inc. (SGMO) effectively leverages its workforce, generating an average of -$595136.61 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.88% and a Quick Ratio of 0.88%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Sangamo Therapeutics Inc [SGMO] stock
With the latest financial reports released by the company, Sangamo Therapeutics Inc posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SGMO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sangamo Therapeutics Inc go to 73.79%.
Sangamo Therapeutics Inc [SGMO]: Institutional Ownership
There are presently around $18.48%, or 18.84%% of SGMO stock, in the hands of institutional investors. The top three institutional holders of SGMO stocks are: WASATCH ADVISORS LP with ownership of 20.09 million shares, which is approximately 9.8509%. ARMISTICE CAPITAL, LLC, holding 14.06 million shares of the stock with an approximate value of $$5.04 million in SGMO stocks shares; and ARMISTICE CAPITAL, LLC, currently with $$4.26 million in SGMO stock with ownership which is approximately 5.8341%.
